https www ye7 fun South Korea's president avoids an impeachment attempt over short-lived martial law

Kamala Harris, Hillary Clinton failed but will US ever elect a female President?Natixis Advisors LLC Has $3.10 Million Position in Camden Property Trust (NYSE:CPT)

Leftists Are Fleeing X for Bluesky, But One Telling Statistic Reveals the Truth About Them

Giants release quarterback Daniel Jones just days after benching him EAST RUTHERFORD, N.J. (AP) — The Daniel Jones era in New York is over. The Giants quarterback was granted his release by the team just days after the franchise said it was benching him in favor of third-stringer Tommy DeVito. New York president John Mara said Jones approached the team about releasing him and the club obliged. Mara added he was “disappointed” at the quick dissolution of a once-promising relationship between Jones and the team. Giants coach Brian Daboll benched Jones in favor of DeVito following a loss to the Panthers in Germany that dropped New York's record to 2-8. Week 16 game between Denver Broncos and Los Angeles Chargers flexed to Thursday night spot The Los Angeles Chargers have played their way into another prime time appearance. Justin Herbert and company have had their Dec. 22 game against the Denver Broncos flexed to Thursday night, Dec. 19. Friday’s announcement makes this the first time a game has been flexed to the Thursday night spot. The league amended its policy last season where Thursday night games in Weeks 13 through 17 could be flexed with at least 28 days notice prior to the game. The matchup of AFC West division rivals bumps the game between the Cleveland Browns and Cincinnati Bengals to Sunday afternoon. NBA memo to players urges increased vigilance regarding home security following break-ins MIAMI (AP) — The NBA is urging its players to take additional precautions to secure their homes following reports of recent high-profile burglaries of dwellings owned by Milwaukee Bucks forward Bobby Portis and Kansas City Chiefs teammates Patrick Mahomes and Travis Kelce. In a memo sent to team officials, a copy of which was obtained by The Associated Press, the NBA revealed that the FBI has connected some burglaries to “transnational South American Theft Groups” that are “reportedly well-organized, sophisticated rings that incorporate advanced techniques and technologies, including pre-surveillance, drones, and signal jamming devices.” Nick Chubb plows through heavy snow for 2-yard TD, giving Browns 24-19 win over Steelers CLEVELAND (AP) — Nick Chubb ran for a 2-yard touchdown in heavy snow with 57 seconds left, and the Cleveland Browns stunned division rival Pittsburgh 24-19, ending the Steelers’ five-game winning streak. The Browns had blown a 12-point lead in the fourth quarter and were down 19-18 before getting the ball back with 3:22 remaining after Pittsburgh punter Corliss Waitman shanked a 16-yarder. With snow piling up and covering the yard lines on the field, Cleveland’s Jameis Winston completed a third-down pass to Jerry Jeudy to the Pittsburgh 9. Two plays later, Chubb barreled into the end zone. The AFC North-leading Steelers fell to 8-3 while the Browns are 3-8. Shohei Ohtani in early stages of rehab from shoulder surgery and hopes to be ready for opening day LOS ANGELES (AP) — Shohei Ohtani is in the early stages of rehabilitation from left shoulder surgery after the World Series. The Los Angeles Dodgers superstar says the goal is for him to be ready to pitch and hit by opening day next March, but he's going to be conservative in his approach and make sure he's totally healthy first. Ohtani won his third MVP award Thursday, and first in the National League. He was in Los Angeles with his wife and beloved dog, Decoy, although because of his surgery four days after the Dodgers' World Series victory over the New York Yankees, the family hasn't been able to celebrate. Caitlin Clark to join Cincinnati bid for 16th National Women's Soccer League team WNBA star Caitlin Clark has joined Cincinnati’s bid for an expansion National Women’s Soccer League team. Major League Soccer franchise FC Cincinnati is heading the group vying to bring a women’s pro team to the city. The club issued a statement confirming Clark had joined the bid group. NWSL Commissioner Jessica Berman has said the league plans to announce the league’s 16th team by the end of the year. The league's 15th team will begin play in 2026 in Boston. Shohei Ohtani wins third MVP award, first in NL. Aaron Judge earns second AL honor in 3 seasons NEW YORK (AP) — Shohei Ohtani won his third Most Valuable Player Award and first in the National League, and Aaron Judge earned his second American League honor on Thursday. Ohtani was a unanimous MVP for the third time, receiving all 30 first-place votes and 420 points in voting by the Baseball Writers’ Association of America. New York Mets shortstop Francisco Lindor was second with 263 points and Arizona second baseman Ketel Marte third with 229. Judge was a unanimous pick for the first time. Kansas City shortstop Bobby Witt Jr. got all 30 second-place votes for 270 points, and Yankees outfielder Juan Soto was third with 21 third-place votes and 229 points. Athletes see climate change as threatening their sports and their health. Some are speaking up BAKU, Azerbaijan (AP) — Pragnya Mohan has been a professional triathlete for nearly a decade, but summers in her native India are now so hot that she can’t train there anymore. And she worries about a day when heat around the world kills her sport entirely. She was among athletes who spoke at the United Nations climate summit in Azerbaijan about the threat global warming poses to them, to fans and to sport itself. They described how extreme weather is making training and competing difficult or impossible. With billions of fans worldwide, some athletes and leagues are trying to get more people to care, and act, on climate change. Martin Slumbers hangs his hat on making British Open big and promoting women's golf Martin Slumbers brought a business background to his role as CEO of the R&A. He made it his business to make the British Open big with commercialization and large galleries. Slumbers also expanded the R&A's championships by acquiring the Ladies Golf Union. That put the R&A in charge of the Women's British Open. The prize money has nearly tripled and the women have gone to the best links. Slumbers considers these big achievements as he retires at the end of the year after nine years on the job. He says he hopes to see golf's divided landscape put back together. Alex Ovechkin is expected to miss 4 to 6 weeks with a broken left leg Alex Ovechkin has a broken left fibula and is expected to be out four to six weeks. The Washington Capitals confirmed Ovechkin’s injury and prognosis Thursday after he was evaluated by doctors upon the teams’ return from a three-game road trip. This prolonged absence puts a pause on Ovechkin’s pursuit of Wayne Gretzky’s NHL career goals record. He scored 15 goals in his first 18 games this season to move just 27 away of passing Gretzky. Ovechkin was on pace to break the record in February before his shin-on-shin collision with Utah’s Jack McBain on Monday night.Timothée Chalamet stuns fans with college football knowledge after criticism for being named ESPN guest picker

Empowered Funds LLC boosted its stake in shares of Core Molding Technologies, Inc. ( NYSEAMERICAN:CMT – Free Report ) by 5.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,182 shares of the industrial products company’s stock after purchasing an additional 1,742 shares during the quarter. Empowered Funds LLC owned about 0.41% of Core Molding Technologies worth $623,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Royce & Associates LP grew its position in shares of Core Molding Technologies by 7.2% during the 3rd quarter. Royce & Associates LP now owns 149,244 shares of the industrial products company’s stock worth $2,568,000 after purchasing an additional 10,000 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its stake in shares of Core Molding Technologies by 10.4% in the third quarter. Diamond Hill Capital Management Inc. now owns 149,320 shares of the industrial products company’s stock valued at $2,570,000 after buying an additional 14,039 shares during the period. Inspire Advisors LLC acquired a new stake in Core Molding Technologies during the third quarter worth approximately $326,000. Tieton Capital Management LLC increased its stake in Core Molding Technologies by 151.9% during the 2nd quarter. Tieton Capital Management LLC now owns 177,521 shares of the industrial products company’s stock worth $2,830,000 after acquiring an additional 107,041 shares during the period. Finally, American Century Companies Inc. raised its holdings in Core Molding Technologies by 19.1% in the 2nd quarter. American Century Companies Inc. now owns 176,950 shares of the industrial products company’s stock valued at $2,821,000 after acquiring an additional 28,376 shares in the last quarter. 58.79% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets Separately, StockNews.com raised shares of Core Molding Technologies from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Insider Buying and Selling In other Core Molding Technologies news, CFO John P. Zimmer sold 13,653 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $18.30, for a total transaction of $249,849.90. Following the sale, the chief financial officer now owns 115,559 shares of the company’s stock, valued at approximately $2,114,729.70. This represents a 10.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink . Insiders have sold a total of 15,749 shares of company stock valued at $287,678 over the last ninety days. 13.10% of the stock is owned by company insiders. Core Molding Technologies Price Performance Shares of CMT stock opened at $17.50 on Friday. The stock has a market cap of $156.80 million, a PE ratio of 9.89 and a beta of 1.69. The company has a current ratio of 2.41, a quick ratio of 1.98 and a debt-to-equity ratio of 0.14. Core Molding Technologies, Inc. has a 12 month low of $14.64 and a 12 month high of $21.00. Core Molding Technologies ( NYSEAMERICAN:CMT – Get Free Report ) last announced its quarterly earnings results on Tuesday, November 5th. The industrial products company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.13. The firm had revenue of $72.99 million during the quarter, compared to analysts’ expectations of $71.57 million. Core Molding Technologies had a net margin of 4.95% and a return on equity of 10.76%. Analysts predict that Core Molding Technologies, Inc. will post 1.64 earnings per share for the current year. Core Molding Technologies Company Profile ( Free Report ) Core Molding Technologies, Inc, together with its subsidiaries, operates as a molder of thermoplastic and thermoset structural products. The company offers a range of manufacturing processes that include compression molding of sheet molding compound, resin transfer molding, liquid molding of dicyclopentadiene, spray-up and hand-lay-up, direct long-fiber thermoplastics, and structural foam and structural web injection molding. Read More Receive News & Ratings for Core Molding Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Molding Technologies and related companies with MarketBeat.com's FREE daily email newsletter .White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign

Maple Leafs hit quarter mark of season in a good spot, but aren't satisfied yet

Vikings thrive under coach of year favorite O'Connell, a relatable state for Packers with LaFleurBrooklyn Burn Injury Attorney Samantha Kucher Releases In-Depth Article on Burn Injuries in Brooklyn

Bitcoin tops $100,000 as monster 2024 rally reaches new heightsStock market today: Stocks waver in thin trading after US markets reopen following a holiday pause

None

Liverpool v Leicester: Premier League – liveBlame it on the food and drink?

New Delhi: The passing of Dr Manmohan Singh has sent a wave of mourning across the nation. Leaders from both ruling and opposition parties expressed grief over his demise and remembered his contributions. ET Year-end Special Reads Corporate Kalesh: Top family disputes of India Inc in 2024 The world of business lost these eminent people in 2024 Fast, faster, fastest: How 2024 put more speed into your shopping President Droupadi Murmu in her condolence message said that Singh was one of the rare politicians who also straddled the worlds of academia and administration with equal ease. "In his various roles in public offices, he made critical contributions to reforming the Indian economy. He will always be remembered for his service to the nation, his unblemished political life and his utmost humility," President Murmu wrote on X. Congress president Mallikarjun Kharge in his condolence message said that Singh was a great individual, who believed in actions more than words, and made invaluable contributions to nation-building. "I mourn the loss of my senior colleague, a gentleman scholar, and a humble soul who realised India's aspirations with unwavering dedication...his invaluable contributions will remain forever etched in Indian history," Kharge wrote on X. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program Union home minister Amit Shah said that Dr. Singh played a pivotal role in the country's governance. "I am deeply saddened to hear about the demise of former Prime Minister Dr. Manmohan Singh Ji. From serving as the Governor of the RBI to Finance Minister and then Prime Minister, Dr Singh played a pivotal role in the country's governance. May Waheguru Ji grant his soul eternal peace...," Shah wrote on X. Congress leader Priyanka Gandhi said that his honesty will always be an inspiration for us and he will forever stand tall among those who truly love this country as someone who remained steadfast in his commitment to serve the nation despite being subjected to unfair and deeply personal attacks by his opponents. Former PM and senior JDS leader HD Deve Gowda said- "He was a good and patient man, a brilliant economist, and a colleague I valued and respected. He will be remembered in history as the man who changed the course of India's economic future." West Bengal CM Mamata Banerjee in her condolence message said that his contributions to financial reforms are widely appreciated. "Having worked with him closely in the central cabinet, I witnessed his wisdom and discretion firsthand. The nation will remember his leadership, and I will miss his affectionate presence," Banerjee wrote on X. NCP leader Sharad Pawar said: "Our nation has lost one of its greatest economists, a visionary reformist, and a global statesman. His departure is an unbearable loss-he was a godly soul who embodied humility, forbearance, tolerance, and compassion. As the architect of India's economic reforms, his legacy will forever inspire generations to come," Pawar wrote on X. (You can now subscribe to our Economic Times WhatsApp channel )SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 8, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024 in San Diego, California. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favor of Polivy in combination with R-CHP compared to Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, M.D., Ph.D., chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% versus 61.7%). At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% versus 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the U.S., countries throughout the EU, the U.K., Japan, Canada and China. Genentech continues to work with health authorities around the world to bring this treatment regimen to even more patients. Genentech aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Genentech is exploring Polivy in combination with other molecules, including its bispecific antibodies. Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the Phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi ® (glofitamab-gxbm) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX Study POLARIX [ NCT03274492 ] is an international Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy ® (polatuzumab vedotin-piiq) plus Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) versus Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomized 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of Rituxan. The primary outcome measure is progression-free survival as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC). About Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin’s lymphoma (NHL) in the U.S. While many people with DLBCL are responsive to treatment, the majority of those who relapse or are refractory to subsequent treatments have poor outcomes. DLBCL not otherwise specified is the most common category of large B-cell lymphoma (LBCL) and accounts for about 80% or more of cases. It applies to cases that do not fall into any specific disease subgroups of LBCL. About Polivy ® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL). Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Side effects seen most often The most common side effects during treatment were Polivy may lower your red or white blood cell counts and increase uric acid levels. Polivy may not be for everyone. Talk to your doctor if you are These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see the full Prescribing Information and visit https://www.Polivy.com for additional Important Safety Information. About Lunsumio ® (mosunetuzumab-axgb) Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin’s lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers. Lunsumio U.S. Indication Lunsumio (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if Lunsumio is safe and effective in children. The conditional approval of Lunsumio is based on response rate. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Lunsumio? Lunsumio may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Lunsumio and can also be severe or life-threatening. Get medical help right away if you develop any signs or symptoms of CRS at any time, including: Due to the risk of CRS, you will receive Lunsumio on a “step-up dosing schedule.” Your healthcare provider will check you for CRS during treatment with Lunsumio and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Lunsumio, if you have severe side effects. What are the possible side effects of Lunsumio? Lunsumio may cause serious side effects, including: Your healthcare provider may temporarily stop or permanently stop treatment with Lunsumio if you develop severe side effects. The most common side effects of Lunsumio include: tiredness, rash, fever, and headache. The most common severe abnormal blood test results with Lunsumio include: decreased phosphate, increased glucose, and increased uric acid levels. Before receiving Lunsumio, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Lunsumio? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. These are not all the possible side effects of Lunsumio. Talk to your healthcare provider for more information about the benefits and risks of Lunsumio. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects, as well as the Lunsumio full Prescribing Information and Medication Guide or visit https://www.Lunsumio.com . About Columvi ® (glofitamab-gxbm) Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is part of Genentech’s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development program that also includes Lunsumio ® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Columvi U.S. Indication Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer. It is not known if Columvi is safe and effective in children. The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Columvi? Columvi can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Columvi, and can also be serious and lead to death. Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including: Due to the risk of CRS, you will receive Columvi on a “step-up dosing schedule”. Your healthcare provider will monitor you for CRS during treatment with Columvi and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Columvi if you have severe side effects. Carry the Columvi Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Columvi Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away. What are the possible side effects of Columvi? Columvi may cause serious side effects, including: The most common side effects of Columvi include: CRS, muscle and bone pain, rash, and tiredness. The most common severe abnormal lab test results with Columvi include: decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting). Your healthcare provider may temporarily stop or completely stop treatment with Columvi if you develop certain side effects. Before receiving Columvi, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Columvi? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems. These are not all the possible side effects of Columvi. Talk to your health care provider for more information about the benefits and risks of Columvi. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects , as well as the Columvi full Prescribing Information and Medication Guide or visit https://www.Columvi.com About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology . About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . Dr. Salles has financial interests related to Roche and Genentech. View source version on businesswire.com : https://www.businesswire.com/news/home/20241208818007/en/ CONTACT: Media Contact: Kristen Ingram, (650) 467-6800Advocacy Contact: Catherine Creme Henry, (202) 258-8228Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, 011 41 61 687 5284 KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY SOURCE: Genentech Copyright Business Wire 2024. PUB: 12/08/2024 12:30 PM/DISC: 12/08/2024 12:30 PM http://www.businesswire.com/news/home/20241208818007/en

Underdog Fantasy Promo Code BETFPB for Arizona vs. Duke: $1,000 bonus for Nov. 22 college basketballNone

Thousands of protesters marched in the Georgian capital Tbilisi Saturday for the 10th day of rallies sparked by a disputed election and the government's decision to shelve EU accession talks. Demanding fresh elections and a return to European integration, the demonstrators headed towards parliament, undeterred by a police crackdown on pro-EU protesters and attacks on the opposition. The Caucasus nation has been engulfed in turmoil since the governing Georgian Dream party declared victory in a disputed October 26 election. The government last week said it would suspend talks to join the European Union, sparking a fresh wave of demonstrations. Its critics accuse it of creeping authoritarianism and of steering the country back towards Russia. Ukraine's leader Volodymyr Zelensky -- whose country has been fighting a Russian invasion for almost three years -- said Saturday he fully backed Georgia's anti-government protesters. Zelensky urged Tbilisi to stop "surrendering" to Moscow in a meeting with the country's pro-EU president Salome Zurabishvili in Paris. He has warned of Russian influence in Georgia for months. Zurabishvili -- at loggerheads with the ruling party -- has denounced widespread fraud in October's parliamentary polls, and branded the freshly elected legislature and government "illegitimate". Blowing horns and whistles, pro-European protesters on Saturday marched from Tbilisi State University towards parliament, blocking one of the city's main traffic arteries, an AFP reporter saw. As on previous nights, some demonstrators banged on the metal barriers blocking the parliament's entrance. Others pointed laser beams at the building and the police blocking the adjacent streets. "They are trying to arrest us, punish us, but we won't back down, we are not afraid," said 19-year-old protester Giorgi Romanadze. "This is our last chance to be free, to be happy. We want Europe, and Europe only." Some demonstrators held signs reading "We demand free and fair elections" and "Free all unjustly arrested," as calls for stronger international backing grew louder among the protesters. "We are fighting for our freedom... and we want the international community to help us," said 32-year-old Teona Chakvetadze. "We need the international community to sanction our oligarchs and this illegitimate government.... We can't win this fight on our own." Independent television station Pirveli reported that dozens of masked men had severely beaten its journalists. Police officers stood by without intervening during the incident near the protest venue. The opposition alliance, For Change, released CCTV footage showing the masked men raiding its office and badly beating opposition figure Koba Khabazi. The Georgian Dream government's security forces had faced persistent accusations of deploying plainclothes security agents to target and attack political opponents. The crackdown has triggered outrage at home and mounting international condemnation. Officers have made hundreds of arrests, including 48 at a protest on Friday. The country's rights ombudsman has accused the police of "torture" against those detained, with scores reporting mistreatment or showing visible injuries. With both sides ruling out a compromise, there appeared to be no clear route out of the crisis. The United States, France and Germany are among the Western countries to have denounced the crackdown on protests, but the government has refused to back down. Prime Minister Irakli Kobakhidze has praised his security forces after several opposition party offices were raided and their leaders arrested. "We have won an important battle against liberal fascism in our country," he told journalists, using language reminiscent of Kremlin rhetoric against its political opponents. Demonstrators have rejected Kobakhidze's characterisation of the protest movement. Thousands have also staged daily protests in other parts of Georgia, including the cities of Batumi, Kutaisi, Rustavi, Zugdidi, and Telavi, local media reported. Critics of Georgian Dream are enraged by what they call its betrayal of the country's bid for EU membership, enshrined in the constitution and supported by around 80 percent of the population. Georgian Dream, in power for more than a decade, has advanced controversial legislation in recent years, targeting civil society and independent media and curbing LGBTQ rights. Brussels has warned that such policies are incompatible with EU membership, while domestic detractors accuse the government of copying Russia's playbook. ub-im/sbkThe Gophers football team resembled its fan base in one respect this week. Current players sat down to watch as their predecessors put together highlight after highlight in Minnesota’s 31-26 upset of Penn State in 2019. ADVERTISEMENT The positive plays were plentiful. Tanner Morgan’s three touchdown passes, including a 66-yard catch and run from Rashod Bateman to open the game; Mariano Sori-Marin’s pressure to force a lofted pass on Antoine Winfield’s second interception of the game; Tyler Johnson’s fighting off pass interference to make a one-handed catch on a 38-yard score; Chris Autman-Bell taking a screen pass and making multiple Nittany Lions miss on a 21-yard TD; Esezi Otomewo’s big sack; and Jordan Howden’s game-sealing pick. With fourth-ranked Penn State coming into Huntington Bank Stadium on Saturday, the Gophers will look to pull off another upset. Their use of highlights fulfills one of their mottos: Embracing the past to create our future. Minnesota (6-4, 4-3 Big Ten) will need to collect a similar amount of big plays and turnovers to pull off an upset as an 11-point underdog to the Nittany Lions (9-1, 6-1). “It’s going to take our best players making plays like that,” head coach P.J. Fleck said about the 2019 victory. “Penn State’s going to say the same thing. We’re going to get their best shot. We know that. I don’t expect anything less from a James Franklin team, but we’ve got to coach them up so they get our best shot, too.” ADVERTISEMENT Back in 2019, the Gophers were 8-0 and ranked 13th in the nation. Penn State was also 8-0 and ranked fourth. Minnesota had not beat a ranked team up to that point and doubt remained that Minnesota could play with traditional powerhouses. After the win and fans stormed the field, the Gophers climbed the College Football Playoff rankings the next week. Five years on, it remains of the best wins of Fleck’s tenure since 2017. “That was a great moment spring-boarding us into what we have done consistently,” Fleck told the Pioneer Press. “Then just giving us that ability that we can and that mindset that we can and we will. It’s just a matter of time. A lot of things have to line up for it to happen, but that is what is so fun about it.” For the yesteryear Penn State game, Gophers defensive end Danny Striggow was a visiting recruit from Orono. He and other recruits were told not to storm the field because they were headed into the locker room postgame. ADVERTISEMENT “That was a cool game,” Striggow said. “... I was there as a recruit, so it’s kind of funny to look back on it, just being able to experience that as a fan and as a recruit.” Now Stiggow will play in his 50th game in maroon and gold. “(We can) look back at what they did to win that game, learn from that game and go forward and apply it,” Striggow said. Quarterback Max Brosmer said the 2019 Penn State game was the first one he watched to prepare for this year’s match-up. ADVERTISEMENT “I was wondering how Minnesota beat them in ’19 and what kind of things worked well for them,” Brosmer said. “... How did they execute the small details well to finish and win that game? We took away some good stuff from that game and we will use that to the best of our advantage.” ______________________________________________________ This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here .

Barclays Issues Positive Forecast for Brown & Brown (NYSE:BRO) Stock Price